Medtronic plc (NYSE:MDT) went down by -0.84% from its latest closing price compared to the recent 1-year high of $135.89. The company’s stock price has collected -3.41% of loss in the last five trading sessions. Press Release reported 6 hours ago that U.S. Patent and Trademark Office Rejects Axonics’ Challenge to Medtronic Patents
Is It Worth Investing in Medtronic plc (NYSE :MDT) Right Now?
Medtronic plc (NYSE:MDT) scored a price-to-earnings ratio above its average ratio, recording 45.36 x from its present earnings ratio. Plus, the 36-month beta value for MDT is at 0.81. Opinions of the stock are interesting as 19 analysts out of 28 who provided ratings for Medtronic plc declared the stock was a “buy,” while 4 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $146.96, which is $15.52 above the current price. MDT currently public float of 1.34B and currently shorts hold a 0.79% ratio of that float. Today, the average trading volume of MDT was 3.87M shares.
MDT’s Market Performance
MDT stocks went down by -3.41% for the week, with a monthly jump of 1.98% and a quarterly performance of 4.74%, while its annual performance rate touched 24.12%. The volatility ratio for the week stands at 1.96% while the volatility levels for the past 30 days are set at 1.60% for Medtronic plc. The simple moving average for the period of the last 20 days is -1.66% for MDT stocks with a simple moving average of 6.15% for the last 200 days.
Analysts’ Opinion of MDT
Many brokerage firms have already submitted their reports for MDT stocks, with Cowen repeating the rating for MDT by listing it as a “Outperform.” The predicted price for MDT in the upcoming period, according to Cowen is $141 based on the research report published on June 10th of the current year 2021.
Barclays, on the other hand, stated in their research note that they expect to see MDT reach a price target of $145. The rating they have provided for MDT stocks is “Equal Weight” according to the report published on May 25th, 2021.
Atlantic Equities gave a rating of “Overweight” to MDT, setting the target price at $153 in the report published on April 15th of the current year.
MDT Trading at 0.37% from the 50-Day Moving Average
After a stumble in the market that brought MDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.30% of loss for the given period.
Volatility was left at 1.60%, however, over the last 30 days, the volatility rate increased by 1.96%, as shares surge +1.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.10% upper at present.
During the last 5 trading sessions, MDT fell by -3.41%, which changed the moving average for the period of 200-days by +14.01% in comparison to the 20-day moving average, which settled at $132.32. In addition, Medtronic plc saw 11.01% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at MDT starting from Lerman Bradley E, who sale 50,775 shares at the price of $134.17 back on Aug 31. After this action, Lerman Bradley E now owns 48,763 shares of Medtronic plc, valued at $6,812,482 using the latest closing price.
Salmon Sean, the EVP & Pres Diabetes/Cardiovasc of Medtronic plc, sale 28,419 shares at $134.08 during a trade that took place back on Aug 25, which means that Salmon Sean is holding 33,329 shares at $3,810,492 based on the most recent closing price.
Stock Fundamentals for MDT
Current profitability levels for the company are sitting at:
- +18.38 for the present operating margin
- +59.70 for the gross margin
The net margin for Medtronic plc stands at +11.97. The total capital return value is set at 7.11, while invested capital returns managed to touch 4.74. Equity return is now at value 7.60, with 4.10 for asset returns.
Based on Medtronic plc (MDT), the company’s capital structure generated 53.29 points at debt to equity in total, while total debt to capital is 34.76. Total debt to assets is 29.44, with long-term debt to equity ratio resting at 52.90. Finally, the long-term debt to capital ratio is 34.51.
When we switch over and look at the enterprise to sales, we see a ratio of 6.44, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 5.96 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.